A phase II, single arm, multicenter study of nilotinib in combination with pegylated interferon ?2b in patients with suboptimal molecular response or stable detectable molecular residual disease after at least two years of imatinib treatment (NordDutchCML

To assess the effect of switching CML patients, who have been treated with imatinib ?2 years and who have stable detectable molecular residual disease between 0.01-1.0% (IS), to the combination of Nilotinib and PegIFN, in terms of the proportion of patients who achieve confirmed MR4.0.